Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (876)	1/7/2002 7:28:54 PM
From: SemiBull	Read Replies (2) \| Respond to of 3044

COR Therapeutics, Inc. Confirms Prior Guidance for Profitable Fourth Quarter of 2001 and for Sales of INTEGRILIN in 2001 COR Updates 2001 INTEGRILIN® Sales Estimates SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Jan. 7, 2002--COR Therapeutics, Inc. (Nasdaq: CORR - news) today confirmed prior guidance of a profit for the fourth quarter and for the full year of 2001, based on unaudited financial data. COR also said that year-end 2001 sales of INTEGRILIN® (eptifibatide) Injection, as reported to COR by its worldwide partner for INTEGRILIN, Schering-Plough Corporation, would be approximately $208 million in the United States and approximately $230 million on a worldwide basis, at the high end of the range of $225 - $230 million worldwide included in guidance previously provided. COR noted that this represents a 34% increase over worldwide sales reported for 2000. COR Therapeutics, Inc. is dedicated to the discovery, development, and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. In addition to the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from the anticipated results discussed in such forward-looking statements, due to factors related to the commercialization of INTEGRILIN and other factors discussed in the Company's SEC reports, including, but not limited to, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001, and Annual Report on Form 10-K for the year ended December 31, 2000. Forward-looking statements are based on current expectations and the Company does not intend to update such information to reflect later events or developments. -------------------------------------------------------------------------------- Contact: COR Therapeutics, Inc. Peter S. Roddy Catherine C. Villegas 650/244-6893 or Burns McClellan, Inc. Media: Lisa Burns Jonathan M. Nugent 212/213-0006

To: Miljenko Zuanic who wrote (876)	1/9/2002 11:50:35 AM
From: Doug	Read Replies (2) \| Respond to of 3044

M.Z: The probability of success in development of a new Breakthru drug has been very low. I believed that using Proteomics and Genomics this would increase. IMCL has clearly show that this is not the case. Infact the risk of skewed data being presented has increased as it is now easier to manipulate data. As such the risk associated with investment in the new age Start ups is no different than the olde ones. Hence they may not deserve the high valuations that thay have. To increase valuation, they must increase success rates or drastically reduce time for each project. Cos like LU, CHIR , MLNM, CRA, HGSI all have excellent world class Labs & good Scientists but lack the focus , zeal and drive to improve shareholders worth. They are driven by an addiction to science which results in a lot of patents , papers and pure research most of which lacks any practical applications in the immediate future. In brief they are not focussed on applied research with set goals ,deliverables and accountability all of which are essential in the making of a great CO. Compare the strides made by the Networking world and that made by the BIo-Tech world. A check of the No of patents/stock price is a good indicator of which Cos have no applied focus. Nevertheless the Scientist gain a big MAC ( Mutual admiration Club) membership , attending seminars around the world, plagiarizing from each other and defending the club against any accountabilty. I am not "short" but a realist.!